Being Alive; March 1992 presented by Mark Katz MD and reported by Jim Stoecker
We have discussed passive immunotherapy a number of times in the past. Locally, the HemaCare study is ongoing, with no results yet available. A recent Journal of Infectious Diseases included the results of a study of passive immunotherapy conducted in Paris. This small study compared nine on the therapy to nine only on AZT. During the course of the study, two of those on passive immunotherapy came down with an opportunistic infection. In contrast, eight in the control group developed an opportunistic infection.
The French researchers found, however, that when the infusions were halted, the patients seemed to get sicker more often than any in the control group. When the transfusions began again, symptoms seemed to recede. It appears that once one starts passive immunotherapy, one may need to stay on it indefinitely.
920301
BA920306
AEGiS is made possible through unrestricted grants from Roxane Laboratories, the National Library of Medicine, and donations from users like you. Always watch for outdated information. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.
This information is designed to support, not replace, the relationship that exists between you and your doctor.